Join the Oncology
Community
Follow Us:  

Commentaries

Commentary - Products Liability
December 29, 2011



Bookmark and Share

Question: A woman developed primary pulmonary hypertension (PPH) 4 years after she had stopped using the prescription weight-loss drug, fenfluramine. The drug is known to cause valvular heart lesions as well as PPH. In a wrongful death lawsuit, her estate won a jury award of $1 billion in compensatory and exemplary damages. The defense appealed the size of the award, and argued that there are no studies demonstrating an association between fenfluramine and an increased risk of PPH that long after cessation of use. Which of the following is incorrect?

 


By Dr. S.Y. Tan

 

A. This is a products liability case.

B. The plaintiff can advance legal theories against the manufacturer based on warranty, negligence, or strict liability (that is, fault-free liability).

C. This can be a stand-alone case or part of a class action lawsuit.

D. The decision will definitely be overturned on appeal.

E. Such cases are frequently settled for a much smaller sum.

Answer: D. When a person is injured by a defective product, be it a car or a prescription drug, he or she can file a cause of action against the manufacturer or others who have placed that item into the stream of commerce. The law governing this general area of product-related injuries, broadly termed products liability, covers more than one specific tort, and the injured plaintiff can recover damages under a number of legal theories. Essentially, the claim is that the product was defective and unsafe, and the injury suffered by the plaintiff was a foreseeable consequence. In the medical field, patients treated with medications can sustain serious, even fatal, complications. Medical devices such as pacemakers and operating room equipment may malfunction and injure. And mass vaccinations do give rise, if rarely, to neurological sequelae and fatalities.

The above hypothetical is taken from an actual Texas case that was settled, presumably for much less than $1 billion, to avoid the unpredictability of an appellate outcome. Although this was a stand-alone case, such cases are frequently part of a class-action suit.

There are three legal theories in a products liability claim: negligence, breach of warranty, and strict products liability. The latter is the most favored, as there is no need to prove fault or warranty. The legal doctrine had its genesis in Greenman v. Yuba Power Products Inc. Mr. Greenman was injured when he used a power tool that was given to him as a gift. He sued the manufacturer, although there was no direct contract of warranty between him and the manufacturer as he did not make the purchase himself. The California Supreme Court went beyond the law of contracts to find the manufacturer liable, and in the process introduced the notion of strict liability, which goes beyond simple negligence, centering instead on whether a product is defective.

The strict liability approach has been adopted, in some cases with modifications, in virtually all jurisdictions. The theory holds that a professional supplier who sells a product that is both defective and unreasonably dangerous is strictly liable to foreseeable plaintiffs. "Defective" is usually defined as product quality that is less than what a reasonable consumer expects. "Unreasonably dangerous" is a conclusion that the risks that result from its condition outweigh the product’s advantages. Strict liability is not about negligence or fault, but about a social policy that shifts to the manufacturer the cost of compensating the injured consumer. To prevail, the plaintiff must show proximate cause, and assumption of risk is still a valid defense.

Current Issue


The Oncology Report Comprehensive reports and expert commentary on the latest advances in cancer treatment from the world's major oncology meetings.

Past issues, click here »


calendar
Jun 1 - 5
Chicago, IL
American Society of Clinical Oncology (ASCO): Annual Meeting
Jun 14 - 17
Amsterdam,
European Hematology Association (EHA): Annual Congress
Jun 18 - 21
Lake Tahoe, NV
American Association for Cancer Research (AACR): Pancreatic Cancer: Progress and Challenges
Jun 20 - 22
Milan,
European Institute of Oncology (IEO): 14th Milan Breast Cancer Conference
Jun 25 - 26
London,
Teenage Cancer Trust (TCT): International Conference
Jun 27 - 30
Barcelona,
European Society for Medical Oncology (ESMO) Conference: World Congress on Gastrointestinal Cancer
Jun 27 - 30
Boston, MA
American Association for Cancer Research (AACR): Chemical Systems Biology
Jun 28 - 30
New York, NY
Multinational Association of Supportive Care in Cancer (MASCC)/ International Society of Oral Oncology (ISOO): International Symposium
Jun 28 - 29
Paris,
WIN 2012 Symposium
Jul 7 - 10
Barcelona,
22nd Biennial Congress of the European Association for Cancer Research
More Calendar »